SCHEMBL4675879

SCHEMBL4675879

O=C(C=C(O)c1nn[nH]n1)c1sccc1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.41
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
CXCR3 P49682 5/20 0.34
LMNA P02545 3/20 0.32
MAPT P10636 2/20 0.32
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
POLB P06746 3/20 0.31
ALDH1A1 P00352 3/20 0.31
KDM4E B2RXH2 1/20 0.31
CYP2C19 P33261 1/20 0.31
HTT P42858 2/20 0.31
S1PR4 O95977 1/20 0.31
HSP90AA1 P07900 1/20 0.31
PKM P14618 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674643 0.90 NPSR1 (0.52) NPSR1TSHRLMNAMAPTPOLB
SCHEMBL4672382 0.90 NPSR1 (0.41) NPSR1KMT2AMEN1CXCR3LMNA
SCHEMBL4676053 0.83 NPSR1 (0.41) NPSR1KMT2AMEN1CYP3A4TSHR
SCHEMBL4671615 0.83 ALDH1A1 (0.35) NPSR1KMT2AMEN1CYP3A4CXCR3
SCHEMBL4676996 0.81 MAPT (0.41) NPSR1KMT2AMEN1CYP3A4CXCR3
SCHEMBL4674683 0.80 AKR1B1 (0.33) KMT2AMEN1CYP3A4CXCR3MAPT
SCHEMBL4673903 0.79 CXCR3 (0.32) KMT2AMEN1CYP3A4CXCR3MAPT
SCHEMBL4673303 0.79 ALDH1A1 (0.33) NPSR1KMT2AMEN1CYP3A4CXCR3
SCHEMBL4678135 0.78 AKR1B1 (0.34) NPSR1KMT2AMEN1CYP3A4CXCR3
SCHEMBL4670921 0.78 CXCR3 (0.31) NPSR1KMT2AMEN1CYP3A4CXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPSR1 937/4885KMT2A 597/4885MEN1 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.